

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF DRUG PRODUCT

Vonapro Tablets 20mg

Vonapro Tablets 10mg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Vonapro Tablets 20mg:

Each film-coated tablet contains:

Vonoprazan fumarate

Equivalent to Vonoprazan.....20mg

Vonapro Tablets 10mg:

Each film-coated tablet contains:

Vonoprazan fumarate

Equivalent to Vonoprazan.....10mg

Excipients of known effect: Mannitol

For full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Vonapro Tablets 20 mg and 10 mg: Red colored, oblong-shaped, biconvex film-coated tablets, plain on both sides.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

Vonapro (Vonoprazan) is indicated for:

- Gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration, prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID) administration.
- Adjunct to *Helicobacter pylori* eradication in the following settings:
Gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphatic tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage gastric cancer or *Helicobacter pylori* gastritis.

4.2 Dosage and Administration

Gastric ulcer and duodenal ulcer

The usual adult dosage for oral use is 20mg of Vonapro (Vonoprazan) administered orally once daily an 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer.

Reflux esophagitis

The usual adult dose for oral use is 20mg of Vonapro (Vonoprazan) administered once daily for a total of 4 weeks of treatment. If that dosing proves insufficient, the administration should be extended, but for no longer than 8 weeks of treatment.

For the maintenance therapy of reflux esophagitis showing recurrence and recrudescence, the dose for oral use is 10mg of Vonapro (Vonoprazan) once daily. However, when the efficacy is inadequate, the dosage may be increased up to 20mg of Vonapro (Vonoprazan) once daily.

Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration

The usual adult dosage is one tablet of 10mg of Vonapro (Vonoprazan) administered orally once daily.

Prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID) administration

The usual adult dosage is one tablet of 10mg of Vonapro (Vonoprazan) administered orally once daily.

Adjunct to Helicobacter pylori eradication

For adults, the following three-drug regimen should be administered orally at the same time twice daily for seven days: 20mg of Vonapro (Vonoprazan), 750mg of amoxicillin hydrate and 200mg of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400mg twice daily.

If Helicobacter pylori eradication with a three-drug regimen comprising a proton pump inhibitor, amoxicillin hydrate and clarithromycin has been unsuccessful, as an alternative treatment, adults should be administered the following three drugs orally twice daily for seven days: 20mg of Vonapro (Vonoprazan), 750mg of amoxicillin hydrate and 250mg of metronidazole.

4.3 Contraindications

Vonoprazan is contraindicated in:

- Patients with hypersensitivity to Vonoprazan or to any excipient of the product.
- Patients receiving atazanavir sulphate, nelfinavir or rilpivirine hydrochloride.

4.4 Special Warnings and Special Precautions for use

General

At the treatment, the course of the disease should closely be observed and the minimum therapeutic necessity should be used according to the disease condition.

In the long-term, treatment with Vonoprazan, close observation by such means as endoscopy should be made.

In the maintenance of healing of reflux esophagitis, Vonoprazan should be administered only to the patients who repeat recurrence and recrudescence of the condition. Administration to the patients who do not necessitate maintenance of healing should be avoided.

When the healing is maintained over a long period and when there is no risk of recurrence, the dose reduction to a dose of 10mg from a dose 20mg, or suspension of administration should be considered.

Impaired Renal Function

Vonoprazan should be administered with care in patients with renal disorders as a delay in the excretion of Vonoprazan may occur, which may result in an increase in the concentration of Vonoprazan in the blood.

Impaired Hepatic Function

Vonoprazan should be administered with care in patients with hepatic disorders as a in the metabolism and excretion of Vonoprazan may occur, which may result in an increase in the concentration of Vonoprazan in the blood. Hepatic function abnormalities including liver injury have been reported. Discontinuation of Vonoprazan is recommended in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction.

Elevation of intragastric pH

Administration of Vonoprazan results in elevation of intragastric pH and is therefore not recommended to be taken with drugs for which absorption is dependent on acidic intragastric pH. Symptomatic response to Vonoprazan does not preclude the presence of gastric malignancy. It is therefore, necessary to ascertain the ulcer is not of a malignant nature before initiating the administration of this drug.

Clostridium difficile, serious colitis, including pseudomembranous colitis

There is an increased risk of gastrointestinal infection caused by *Clostridium difficile*. Serious colitis accompanied with bloody stools, such as pseudomembranous colitis, may occur due to amoxicillin hydrate or clarithromycin being used for *Helicobacter pylori* eradication, in combination with Vonoprazan. If abdominal pain and frequent diarrhea occur, appropriate measures, such as immediate discontinuation of the treatment, should be taken.

Benign gastric polyps

Benign gastric polyp has been observed in patient on long-term administration of PPIs.

Fractures

An increased risk for osteoporosis-related fractures of the hip, wrist or spine have been reported in patients under treatment with proton pump inhibitors. The risk of fracture was especially increased in the patients receiving high dose or long term (a year or longer) treatment.

Hypomagnesemia

Severe hypomagnesemia has been reported in patients on prolonged treatment with PPIs for at least three months and in most cases for a year.

Use in elderly

Since physiological functions such as hepatic or renal function are decreased in elderly patients in general, Vonoprazan should be carefully administered.

Use in children less than 18 years of age

Vonoprazan has not been studied in patients under 18 years of age.

4.5 Drug Interactions

Vonoprazan should be administered with care when co-administered with the following drugs:

Drugs	Signs	Mechanism & Risk Factors
<i>CYP3A4 inhibitors</i> Clarithromycin etc.	Blood conc. Of Vonoprazan may increase.	It has been reported that blood conc. of Vonoprazan increased in concomitant use with clarithromycin.
Digoxin, Methyldigoxin	Effect of these drugs may be enhanced.	Gastric antisecretory effect of Vonoprazan may inhibit hydrolysis of digoxin, resulting in increase in the blood concentration of digoxin.
<i>Itraconazole, Tyrosine kinase inhibitors Gefitinib, Nilotinib, Erlotinib</i>	Effect of these drugs may be diminished.	Gastric antisecretory effect of Vonoprazan may lead to a decrease in the blood concentration of these drugs.

4.6 Pregnancy and

Lactation Pregnancy

Vonoprazan should be used in pregnant women or women having possibilities of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk.

Nursing Mothers

It is advisable to avoid the administration of Vonoprazan to nursing mothers. However, when the administration is indispensable, nursing should be discontinued.

4.7 Undesirable Effects

The following adverse reactions have been reported with the use of Vonoprazan: Diarrhea, constipation, drug hypersensitivity (including anaphylactic shock), drug eruption, urticaria, hepatotoxicity, jaundice, rash, nausea, abdominal distension, gamma-glutamyl transferase increased, AST increased, Liver function test abnormal, ALT increased, ALP increased, LDH increased, - GPT increased, edema

and eosinophilia.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Regulatory Authority pharmacovigilance reporting channels.

4.8 Overdosage

There is no experience of overdose with Vonoprazan. Vonoprazan is not removed from the circulation by hemodialysis. If overdose occurs, treatment should be symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Mechanism of action

Vonoprazan is a potassium-competitive acid blocker (P-CAB) and does not require activation by acid. It inhibits H⁺, K⁺-ATPase in a reversible and potassium-competitive manner. Vonoprazan has a strong basicity and resides on the acid production site of gastric parietal cells for a long time, thereby inhibiting gastric acid production. Vonoprazan exerts a strong inhibitory effect on the formation of mucosal damage in the upper part of the gastrointestinal tract. Vonoprazan does not exhibit anti-*Helicobacter pylori* activity nor inhibitory activity against *Helicobacter pylori* urease.

Adjunctive effect on eradication of Helicobacter pylori:

The role of Vonoprazan in the *Helicobacter pylori* eradication is considered to increase intragastric pH leading to the enhancement of antibacterial activity of amoxicillin hydrate, clarithromycin and metronidazole which are concomitantly administered.

5.2 Pharmacokinetic properties

Pharmacokinetics at consecutive administration of a daily dose of 10mg or 20mg of Vonoprazan in healthy adult male subjects once daily for 7 days, AUC_(0-tau) and C_{max} increase as the dose increases. The degree of these increases is slightly higher than the dose ratio. It is considered that the steady state has been reached by day 3 of administration, since the trough level of the blood concentration of Vonoprazan is constant between day 3 and day 7 of administration. In addition, it is considered that pharmacokinetics of Vonoprazan at consecutive administration may not be time-dependent, as the result of the evaluation of accumulation with regard to AUC_(0-tau) and T_{1/2} of Vonoprazan

Dose condition	10mg	20mg
Tmax (h)	1.5 (0.75, 3.0)	1.5 (0.75, 3.0)

C _{max} (ng/ml)	12.0 ± 1.8	26.3 ± 6.6
T _{1/2} (h)	7.0 ± 1.6	6.1 ± 1.2
AUC(0-tau) (ng.h/ml)	79.5 ± 16.1	151.6 ± 40.3
Mean ± S.D. of 9 subjects [T _{max} is expressed by the median (minimum value, maximum value)]		

Absorption

Absolute bioavailability has not been determined. The pharmacokinetic parameters of Vonoprazan following single administration of Vonoprazan to healthy adult male subjects at 20mg under fasting and fed conditions are presented in the table as follows:

Dose condition	10mg	20mg
T _{max} (h)	1.5 (0.75, 3.0)	1.5 (0.75, 3.0)
C _{max} (ng/ml)	12.0 ± 1.8	26.3 ± 6.6
T _{1/2} (h)	7.0 ± 1.6	6.1 ± 1.2
AUC(0-tau) (ng.h/ml)	79.5 ± 16.1	151.6 ± 40.3
Mean ± S.D. of 9 subjects [T _{max} is expressed by the median (minimum value, maximum value)]		

Distribution

The protein binding rate is 85.2 to 88.0% when [¹⁴C] Vonoprazan in the range of 0.1 to 10µg/mL is added to human plasma (in vitro).

Metabolism

Vonoprazan is metabolized mainly by hepatic drug-metabolizing enzyme CYP3A4 and partially by CYP2B6, CYP2C19 and CYP2D6. Vonoprazan is also metabolized by sulfotransferase SULT2A1 (in vitro).

Vonoprazan exhibits a time-dependent inhibitory effect on CYP2B6, CYP2C19 and CYP3A4/5 (in vitro). In addition, Vonoprazan shows a slight concentration-dependent inductive effect on CYP1A2 but it shows little inductive effect on CYP2B6 and CYP3A4/5 (in vitro).

Elimination

When a radioactive-labelled drug (15mg as Vonoprazan) is orally administered to healthy adult male subjects, 98.5% of the radioactivity administered is excreted into urine and feces by 168 hours after administration: 67.4% into urine and 31.1% into feces.

Patients with special populations

Patients with renal impairment

The effect of renal disorders on pharmacokinetics of Vonoprazan in subjects with

normal renal function, patients with mild, moderate, and severe renal disorder and patients with end-stage renal disease (ESRD) when administered the drug as a single dose of Vonoprazan 20mg shows that AUC_{∞} and C_{max} were higher by 1.3 to 2.4 times and 1.2 to 1.8 times, respectively, in patients with mild, moderate, and severe renal disorder compared to subjects with normal renal function, showing an increase with a reduction in renal function. AUC_{∞} and C_{max} were higher by 1.3 times and 1.2 times, respectively, in ESRD patients compared to those in subjects with normal renal function.

Patients with hepatic impairment

The effect of hepatic disorders on pharmacokinetics in subjects with normal hepatic function and patients with mild, moderate and severe hepatic disorder when administered the drug as a single dose of Vonoprazan 20mg shows that AUC_{∞} and C_{max} were higher by 1.2 to 2.6 times and 1.2 to 1.8 times, respectively, in patients with mild, moderate and severe hepatic disorder, compared to subjects with normal hepatic function.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

- Mannitol
- Avicel PH 101 (Microcrystalline Cellulose)
- Klucel LF Pharm (HPC)
- Fumaric Acid
- Purified Water
- Croscarmellose Sodium
- Magnesium Stearate
- Methocel E-5 (HPMC 5CPS)
- Titanium Dioxide
- Macrogol (P.E.G 6000)
- Ferric Oxide Red

6.2 Incompatibilities

None

6.3 Shelf-life

2 Years

The expiration date refers to the product correctly stored in the required conditions.

6.4 Special precautions for storage

Do not store above 30°C.

Protect from sunlight and moisture.

The expiration date refers to the product correctly stored at the required conditions.

6.5 Nature and contents of container

Vonapro (Vonoprazan) Tablets 20mg are available in Alu-PVDC blister packs of 1 x 14's tablets in a unit carton along with a package insert.

6.6 Instructions for use/handling

- Keep out of reach of children.
- To be sold on prescription of a registered medical practitioner only.

7. MARKETING AUTHORISATION HOLDER

Getz Pharma (Private) Limited
Plot No. 29-30, Sector 27, Korangi Industrial Area,
Karachi-74900, Pakistan
Tel: (92-21) 111-111-511
Fax: (92-21) 5057592

8. MARKETING AUTHORISATION NUMBER

VONAPRO 20MG TABLET: H2022/CTD10289/21242

VONAPRO 10MG TABLET: H2022/CTD10288/21245

9. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION

Date of first authorization:

VONAPRO 20MG TABLET: 20/11/2023

VONAPRO 10MG TABLET: 20/11/2022

10. Date of revision of the text

Last revised on 20-November-2023